» Articles » PMID: 37367035

Characterization of Mammary Tumors Arising from MMTV-PyVT Transgenic Mice

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2023 Jun 27
PMID 37367035
Authors
Affiliations
Soon will be listed here.
Abstract

Among genetically engineered mouse models of breast cancer, MMTV-PyVT is a mouse strain in which the oncogenic polyoma virus middle T antigen is driven by the mouse mammary tumor virus promoter. The aim of the present study was to perform morphologic and genetic analyses of mammary tumors arising from MMTV-PyVT mice. To this end, mammary tumors were obtained at 6, 9, 12, and 16 weeks of age for histology and whole-mount analyses. We conducted whole-exome sequencing to identify constitutional and tumor-specific mutations, and genetic variants were identified using the GRCm38/mm10 mouse reference genome. Using hematoxylin and eosin analysis and whole-mount carmine alum staining, we demonstrated the progressive proliferation and invasion of mammary tumors. Frameshift insertions/deletions (indels) were noted in the Muc4. Mammary tumors showed small indels and nonsynonymous single-nucleotide variants but no somatic structural alterations or copy number variations. In summary, we validated MMTV-PyVT transgenic mice as a multistage model for mammary carcinoma development and progression. Our characterization may be used as a reference for guidance in future research.

Citing Articles

Cyclophosphamide- and doxorubicin-induced impairment of high affinity choline uptake and spatial memory can be prevented by dietary choline supplementation in breast tumor bearing mice.

Botelho R, Kirstein C, Philpot R PLoS One. 2024; 19(11):e0305365.

PMID: 39570894 PMC: 11581227. DOI: 10.1371/journal.pone.0305365.


Genomic Fabrics of the Excretory System's Functional Pathways Remodeled in Clear Cell Renal Cell Carcinoma.

Iacobas D, Obiomon E, Iacobas S Curr Issues Mol Biol. 2023; 45(12):9471-9499.

PMID: 38132440 PMC: 10742519. DOI: 10.3390/cimb45120594.

References
1.
Menezes M, Das S, Emdad L, Windle J, Wang X, Sarkar D . Genetically engineered mice as experimental tools to dissect the critical events in breast cancer. Adv Cancer Res. 2014; 121:331-382. PMC: 4349377. DOI: 10.1016/B978-0-12-800249-0.00008-1. View

2.
Sondka Z, Bamford S, Cole C, Ward S, Dunham I, Forbes S . The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018; 18(11):696-705. PMC: 6450507. DOI: 10.1038/s41568-018-0060-1. View

3.
Ross C, Szczepanek K, Lee M, Yang H, Qiu T, Sanford J . The genomic landscape of metastasis in treatment-naïve breast cancer models. PLoS Genet. 2020; 16(5):e1008743. PMC: 7282675. DOI: 10.1371/journal.pgen.1008743. View

4.
Attalla S, Taifour T, Bui T, Muller W . Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. Oncogene. 2020; 40(3):475-491. PMC: 7819848. DOI: 10.1038/s41388-020-01560-0. View

5.
Vargo-Gogola T, Rosen J . Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007; 7(9):659-72. DOI: 10.1038/nrc2193. View